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Summary
Background Globally, tobacco smoking remains the largest preventable cause of premature death. The COVID-19
pandemic has forced nations to take unprecedented measures, including ‘lockdowns’ that might impact tobacco
smoking behaviour. We performed a systematic review and meta-analyses to assess smoking behaviour changes during the early pre-vaccination phases of the COVID-19 pandemic in 2020.
Methods We searched Medline/Embase/PsycINFO/BioRxiv/MedRxiv/SSRN databases (January−November 2020)
for published and pre-print articles that reported specific smoking behaviour changes or intentions after the onset of
the COVID-19 pandemic. We used random-effects models to pool prevalence ratios comparing the prevalence of
smoking during and before the pandemic, and the prevalence of smoking behaviour changes during the pandemic.
The PROSPERO registration number for this systematic review was CRD42020206383.
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Findings 31 studies were included in meta-analyses, with smoking data for 269,164 participants across 24 countries.
The proportion of people smoking during the pandemic was lower than that before, with a pooled prevalence ratio of
0¢87 (95%CI:0¢79−0¢97). Among people who smoke, 21% (95%CI:14−30%) smoked less, 27% (95%CI:22−32%)
smoked more, 50% (95%CI:41%-58%) had unchanged smoking and 4% (95%CI:1−9%) reported quitting smoking.
Among people who did not smoke, 2% (95%CI:1−3%) started smoking during the pandemic. Heterogeneity was
high in all meta-analyses and so the pooled estimates should be interpreted with caution (I2>91% and p-heterogeneity<0¢001). Almost all studies were at high risk of bias due to use of non-representative samples, non-response
bias, and utilisation of non-validated questions.
Interpretation Smoking behaviour changes during the first phases of the COVID-19 pandemic in 2020 were highly
mixed. Meta-analyses indicated that there was a relative reduction in overall smoking prevalence during the pandemic, while similar proportions of people who smoke smoked more or smoked less, although heterogeneity was
high. Implementation of evidence-based tobacco control policies and programs, including tobacco cessation services,
have an important role in ensuring that the COVID-19 pandemic does not exacerbate the smoking pandemic and
associated adverse health outcomes.
Funding No specific funding was received for this study.
Copyright Ó 2022 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND IGO license
(http://creativecommons.org/licenses/by-nc-nd/3.0/igo/)
Keywords: Smoking; Tobacco; COVID-19; Coronavirus; Systematic review
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Introduction
Coronavirus disease 2019 (COVID-19) has caused substantial morbidity and mortality globally, with over
430 million people infected, resulting in over
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Research in context
Evidence before this study
Emerging evidence indicates that the COVID-19 pandemic has impacted many aspects of everyday life,
including lifestyle behaviours. We searched the Medline,
Embase, and PsycInfo databases, the BioRxiv and MedRxiv pre-print servers, and the SSRN website using search
terms relating to COVID-19 and tobacco smoking, with
no language restrictions, for published studies and preprints up to 5 November 2020 that assessed the relationship between the ﬁrst pre-vaccination phases of the
COVID-19 pandemic and smoking prevalence or smoking behaviour changes. No existing systematic reviews
with meta-analyses were identiﬁed, which was further
conﬁrmed in June 2021 by searches of two key
databases, UNCOVER and the US Veterans’ Affairs
COVID-19 Evidence Review, that aggregate evidence
reviews for COVID-19.
Added value of this study
To our knowledge, this is the most comprehensive systematic review on the COVID-19 pandemic and smoking
to date, including over 269,000 participants from 24
countries covering multiple regions of the world. The
meta-analyses provided pooled estimates describing
smoking prevalence and diverse smoking behaviour
changes, including increased, decreased and stable
tobacco consumption, cessation and initiation, as well
as varied intended and attempted efforts to quit smoking during the pandemic, relative to pre-pandemic
times. In addition, we performed a detailed assessment
of risk of bias, adapting existing tools for the speciﬁc
study question, and have highlighted the present status
of the research and evidence gaps for future research in
the area of smoking behavioural changes during the
COVID-19 pandemic.
Implications of all the available evidence
In addition to the direct population health impact of
COVID-19, the pandemic is likely to affect the future
burden of other diseases, due in part to the concomitant changes in risk factors such as the consumption of
tobacco products. This review focused on tobacco
smoking, and provides important evidence to guide
policy to ensure that tobacco control strategies are
implemented and maintained, and that individuals are
encouraged and supported to avoid consumption of
tobacco products into the future. The methods used in
this review, including tools assessing the risk of bias can
be extended to other studies, in particular those assessing other forms of behavioural change during the
pandemic.

5¢9 million deaths as of 1 March 2022, including over
67 million cases and 1¢6 million deaths in the pre-vaccination phases of the pandemic prior to 7 December

2

2020.1 Reducing the spread of the disease has been a
major priority for governments worldwide, which have
relied on the introduction of various containment measures, including testing and tracing programmes, mandatory isolation and quarantine, travel restrictions,
social/physical distancing, and stay-at-home orders,
especially in the early pre-vaccination phases of the pandemic. Since WHO declared COVID-19 a pandemic on
11 March 2020,2 evidence has emerged of its profound
impact on individuals and communities, affecting physical and mental health3 and increasing financial distress. These effects may translate into lifestyle changes,
including transitions to either more or less healthy
behaviours, which in the longer-term may affect individuals’ disease risk and the consequent population-wide
disease burden.
Tobacco is a major cause of disease burden worldwide,
accounting for 15¢4% of all deaths (8¢71 million) in 2019,4
largely due to smoking-related non-communicable diseases. Early online surveys5,6 reported diverging evidence
on changes in smoking behaviours during the pandemic.
This may reflect a complex interaction between individual,
societal, and structural factors.7−9 Smoking may have
increased for some people as a coping mechanism for psychological distress, including anxiety and/or depression,
and due to other structural factors such as increased opportunity to smoke; however, smoking may have decreased for
others due to reduced access to retailers, limited social
interactions, concerns about health and/or contracting
COVID-19, or financial limitations. Smoking and many of
the chronic diseases it causes (e.g., severe asthma, chronic
obstructive pulmonary disease, cardiovascular disease)
have also been proposed as risk factors for more severe
COVID-19 infection outcomes (e.g., intensive care admission or mortality),10−12 reports of which may have led to
increased attempts to quit smoking during the pandemic.
Given the long-term impact of smoking behaviour
on the future burden of disease, knowledge of smoking
behaviour changes during the COVID-19 pandemic is
important to inform recovery and preventive health
efforts. Therefore, we aimed to systematically review the
literature to evaluate the impact of the first pre-vaccination phases of the COVID-19 pandemic in 2020 (i.e.,
before the mass roll-out of vaccines in some, mostly
high-income countries, and the emergence of the delta
strain) on tobacco smoking behaviours, covering many
aspects of tobacco smoking including prevalence, intensity, uptake or cessation. We synthesised the evidence
using meta-analyses, conducted an in-depth risk of bias
assessment, and identified evidence gaps requiring
future research efforts.

Methods
This systematic review is reported according to the Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) checklist.
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Search strategy and selection criteria

Data extraction

We searched Medline (including MEDLINE Epub
Ahead of Print, I-Process & Other Non-Indexed Citations), Embase, and PsycInfo databases on the OVID
platform by combining database-specific subject headings and text terms for studies in humans on COVID19 and tobacco smoking (CC). There were no language
restrictions, and searches were undertaken to 5 November 2020. We also screened all COVID-19 related
records on the BioRxiv and MedRxiv pre-print servers
(https://connect.biorxiv.org/relate/content/181), and the
SSRN website (https://www.ssrn.com/index.cfm/en/
coronavirus/) to 5 November 2020. Supplementary
Table 1 shows the detailed search strategies. We checked
reference lists of relevant systematic reviews and all
articles included in full-text screening for additional
studies.
We included cross-sectional studies, cohort studies, and uncontrolled “before-and-during” studies
that reported changes in tobacco smoking behaviours
among the general population, smokers, non-smokers or ex-smokers, after the onset of the COVID-19
pandemic. We specifically sought studies that
reported the tobacco smoking prevalence before and
during the COVID-19 pandemic, and/or tobacco
smoking increases, decreases, initiation, cessation,
intentions or attempts to quit during the pandemic
or related restrictions. The definitions of each smoking behaviour change were as reported in the
included studies. For the analyses of changes in
smoking intensity, where possible, only participants
who smoked both before and during the pandemic
were included. Many primary studies did not
describe clearly whether specific estimates for
increases or decreases in smoking intensity included
participants who started or quit smoking during the
pandemic, respectively, or it was clear that those
who started or quit smoking were included. Included
studies are labelled with the following categories in
Tables 1a and 1b: quitting/initiation not included,
quitting/initiation included, or unclear whether quitting/initiation is included. We included non-peerreviewed pre-print publications, and letters, editorials, comments and published peer-reviewed articles.
Conference abstracts, qualitative studies and studies
restricted to populations with specific health conditions, occupations or employment status were
excluded.
Titles and abstracts of identified articles were
screened by one reviewer (SH). The full text of each
potentially relevant article was independently assessed
for inclusion by two reviewers (chosen from PS, CJC,
CC, IS, AM) using pre-specified selection criteria. Disagreements were resolved by third-reviewer adjudication (SH).

Study characteristics and results of eligible studies were
independently extracted by pairs of reviewers (chosen
from PS, CJC, PV, EL, SE, JS, IS, AM, SH) with disagreements resolved by a third reviewer. We extracted
information on study characteristics (publication type,
study design, population source, sampling methods,
survey modality, period, and country), severity and dates
of COVID-19 restrictions,13 participants’ information
(number, age, sex, and smoking status), tobacco smoking prevalence, intensity (mean or category frequencies)
and changes (smoking prevalence, increases, decreases,
intensity, initiations, cessations, intentions and
attempts to quit) before and during the COVID-19 pandemic. Information from the study protocol and study
website were also extracted, where available.
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Risk of bias assessment
For each study, risk of bias assessment was performed
by pairs of independent reviewers (chosen from PS,
CJC, EL, PV, DO’C, IS). Differences were first discussed
as a team, and if consensus was not reached, the item
was independently assessed by a third reviewer (DO’C).
We used two separate risk of bias assessment tools that
were modified for our review. Cross-sectional studies
were assessed using a risk of bias tool based on one for
prevalence studies.14 Cohort studies and uncontrolled
before-and-during studies were assessed using an adaptation of the ROBINS-I tool.15 In summary, the modified cross-sectional study tool and modified before-andafter study tool assessed biases using nine domains and
four domains, respectively (with full details shown in
Supplementary Tables 3, 4), and a summary provided in
the Additional Methods (Supplementary material p.2).
Overall risk of bias for each study was assigned as the
highest risk of bias rating in any domain for that study.

Data synthesis and meta-analysis
We extracted frequencies, prevalences, odds ratios, prevalence ratios, absolute differences in proportions, and
mean differences as applicable to each outcome and
study design. We calculated the effects based on
reported data where possible (see Supplementary material p.2). For the outcomes “smoking more”, “smoking
less”, “smoking initiation” and “smoking cessation”
during the COVID-19 pandemic, the prevalence of the
outcome was the measure of effect. For the outcome
“smoking quantity”, our preferred measure of effect
was the mean difference in smoking quantity before
and during the pandemic but as none of the three studies that reported this outcome provided sufficient information to calculate the standard error of the change,
meta-analysis was not performed.
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A. Cross-sectional studies (164,184 participants in 27 studies).
Country /
Population source*
Sampling
Authors
method

Surveymode

Survey period
(2020)

Participants

27 Jun - 20 Jul

S + NS

Sample characteristics:
N, age, sex

Tobacco smoking prevalence
Reported
by study

WHO
estimate68

1222,

25¢6%

23¢5%

Outcome reportedy

Bangladesh
Ahmedz,29

Social media for online survey;

Convenience

Online and

NR for face-to-face survey

face-to-face

(313/1222)

Mean: 30¢8 (SD: 12¢1),
M: 61¢4%, F: 38¢1%

Smoking changes

M: 46¢6%

All participants

F: 1¢0%

Smoking more: 1¢6% (20/1222)

(2018)

(increased or initiated)
Smoking less: 12¢4% (152/1222)
(reduced or quit)
Smokers
Smoking more: 6¢4% (20/313)
(increased or initiated)
Smoking less: 48¢6% (152/313)
(reduced or quit)

Belgium
Vanderbruggen53

Social media; university
communications; website

Convenience

Online

9−29 Apr

S + NS

3632,

15¢4%
(558/3632)

19¢4%

Smoking prevalence

M: 24¢5%

Before pandemic: 15¢4% (558/3632)

M: 29¢8%, F: 70¢0%,

F: 14¢6%

During pandemic: 15¢3% (556/3632)

Gender-neutral: 0¢2%

(2018)

Smoking changes

Mean: 42¢1 (SD: 14¢6),

All participants
Smoking more: 6¢3% (229/3632)
(increased only − no initiation)
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Smoking less: 2¢5% (reduced or quit)
Smokers
Smoking more: 43¢9% (229/522)
(increased only − no initiation)
Stopped smoking: 6¢5% (36/558)
Non-smokers
Started smoking: 1¢1% (34/3074)

Table 1a (Continued)
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Brazil
Brazil
Malta43

Contacts of authors

Convenience; snowballing

Online

24 Apr - 24 May

S + NS

12¢0%

45,161,

12¢6%

Smoking changes

18−29: 24¢7%, 30−49: 39¢1%, 50+: 36¢2%,

M: 15¢9%

All participants

M: 46¢4%, F: 53¢6%

F: 9¢6%

Smoking less: 1¢5% (reduced only −

(2019)

no quitting)
Smokers
Smoking more: 34¢0% (unclear if
includes initiation)
Smoking less: 12¢1% (reduced only −
no quitting)

China
Ren47

Mobile phone users

Convenience; s

Online

14 Feb - 29 Mar

S + NS

nowballing

1172,
Median: 22¢0 (Q1-Q3: 21¢0−37¢0),

7¢1%
(83/1172)

M: 30¢7%, F: 69¢3%
Sun51

Social media; website

Convenience

Online

24−31 Mar

S + NS

6416,
Mean: 28¢2 (SD: 9¢2),
M: 47%, F: 53%

12¢8%
(822/6416)

26¢6%
M: 50¢5%

Smoking changes
Smokers

F: 2¢1%

Smoking more: 30¢1% (25/83)

(2018)

(unclear if includes initiation)
Smoking prevalence
Before pandemic: 12¢8% (822/
6416)
During pandemic: 13¢6% (873/
6416)
Smoking changes
All participants
Smoking more: 1¢7% (108/6416)
(increased only − no initiation)
Smokers
Smoking more: 21¢6% (108/605)
(increased only − no initiation)
Stopped smoking: 10¢1% (83/
822)
Non-smokers
Started smoking: 2¢4% (134/
5594)

Table 1a (Continued)
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China

Yan54

Social media

Convenience

Online

25 Apr - 11 May

S + NS

13¢8%

9016,
18−29: 48¢9%, 30−39: 33¢4%, 40+: 17¢7%,

Smoking changes

(1248/9016)

All participants

M: 42¢6%, F: 57¢4%

Smoking less: 3¢1% (278/9016)
(unclear if includes quitting)
Smokers
Smoking more: 49¢2% (614/
1248) (unclear if includes initiation)
Smoking less: 22¢3% (278/1248)
(unclear if includes quitting)

France
Constant35

Online panel

Representative

Online

8−20 Apr

S + NS

4005,
18−39: 37¢2%, 40−59: 37¢1%, 60+: 25¢8%,

26¢5%
(1062/4005)

M: 48¢8%, F: 51¢2%

30¢4%

Smoking changes

M: 34¢6%

All participants

F: 26¢5%

Smoking less: 4¢4% (177/4005)

(2019)

(unclear if includes quitting)
Smokers
Smoking more: 21¢8% (231/
1062) (unclear if includes initiation)
Smoking less: 16¢7% (177/1062)
(unclear if includes quitting)

Rolland49

Social media;
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national media

Convenience

Online

25−30 Mar

S + NS

11,391,

24¢5%

Smoking changes

16−29: 29¢9%, 30−49: 46¢7%, 50+:

(2792/11,399;

All participants

23¢4% (unweighted percentages),

weighted percentage)

Smoking less: 5¢2% (589/11,399;

M: 22¢4%, F: 77¢1%, Other: 0¢5%
(unweighted percentages)

weighted percentage) (reduced
or quit)
Smokers
Smoking more: 35¢6% (995/
2792; weighted percentage)
(unclear if includes initiation)
Smoking less: 21¢1% (589/2792;
weighted percentage) (reduced
or quit)
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Germany
Georgiadou38

Social media; website;

Convenience

Online

8−18 Apr

S + NS

print media; radio

2150,
18−24: 29%, 25−44: 42%, 45+: 29%,

27¢3%

23¢4%

(582/2130)

M: 34%, F: 66%

Smoking prevalence

M: 26¢4%

Before pandemic: 27¢3% (582/2130)

F: 20¢2%

During pandemic: 24¢7% (523/2115)

(2018)

Smoking changes
All participants
Smoking more: 11¢9% (251/2115)
(increased only − no initiation)
Smoking less: 2¢5% (53/2115)
(reduced only − no quitting)
Smokers
Smoking more: 50¢0% (251/502)
(increased only − no initiation)
Smoking less: 10¢6% (53/502)
(reduced only − no quitting)
Stopped smoking: 11¢5% (65/567)
Non-smokers
Started smoking: 1¢4% (21/1548)

Ghana
Asiamah30

Social media

Convenience; snowballing

Online

4−16 Apr

S + NS

621,
18−24: 18%, 25−44: 57%, 45+: 25%,
M: 65¢4%, F: 34¢6%

27¢9%
(173/621)

NR

Smoking prevalence

M: 3¢5%

Before pandemic: 27¢9% (173/621)

F: 0¢2%

During pandemic: 27¢9% (173/621)

(2017−2018)

Smoking changes
All participants
Smoking less: 0¢0% (0/621) (reduced
only − no quitting)
Smokers
Smoking more: 0¢0% (0/173) (unclear
if includes initiation)
Smoking less: 0¢0% (0/173) (reduced
only − no quitting)
Stopped smoking: 0¢0% (0/173)

Articles
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Hong Kong
Luk42

Landline phone

Random (landline

Telephone

9−23 Apr

S + NS

18¢0% (weighted

1501,

Smoking changes
All participants

30−59: 52¢0%,

F: 2¢1%

Smoking less: 3¢4% (weighted per-

(panel of mobile

60+: 33¢0%

(2018)

phone users)

(unweighted

Smokers

percentages),

Smoking more: 15¢6% (weighted per-

M: 44¢8%, F:

centage) (unclear if includes initia-

55¢2%

tion)

(unweighted

Smoking less: 19¢1% (weighted per-

percentages)

centage) (unclear if includes quitting)

phone users);

18−29: 15¢0%,

mobile phone

convenience

users

percentage)

26¢6%
M: 50¢5%

users; panel of

centage) (unclear if includes quitting)

India
Chopra34

Social media; email

Convenience; snowballing

Online and telephone

15−30 Aug

S + NS

5¢6%

995,
Mean: 33¢3 (SD: 14¢5),

(56/995)

M: 58¢6%, F: 41¢4%

10¢7%

Smoking prevalence

M: 19¢0%

Before pandemic: 5¢6% (56/995)

F: 2¢0%

During pandemic: 4¢7% (47/995)

(2016−2017)

Italy
Cancello31

Social media

Convenience

Online

15 Apr - 4 May

S + NS

490,
≤30: 14¢5%, 31

21¢4%
(105/490)

19¢0%

Smoking changes

M: 23¢3%

Smokers

−60: 65¢1%, >60:

F: 15¢0%

Smoking more: 38% (40/105)

20¢4%,

(2018)4

(increased only − no initiation)
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M: 16¢3%, F:
83¢7%
Di Renzo36

Social media; web-

Convenience

Online

5−24 Apr

S + NS

site; email

3533,
12−17: 5¢1%, 18

25¢1%
(887/3533)

−30: 29¢7%, 31

Smoking prevalence
Before pandemic: 25¢1% (887/
3533)

−50: 42¢2%, 50+:

During pandemic: 21¢8% (771/

23¢0,

3533)

M: 23¢9%, F:
76¢1%
Odone45

Online panel

Representative

Online

27 Apr - 3 May

S + NS

6003,

23¢3%

Smoking prevalence

18−74: Age

Before pandemic: 23¢3%

breakdown NR,

During pandemic: 21¢9%

NR

www.thelancet.com Vol 47 Month May, 2022

Netherlands
Bommele7

Online panel

Representative

Online

11−18 May

S

NA

957,

21¢7%

Smoking changes

Mean: 45¢9 (SD: 16¢4),

M: 25¢4%

M: 56¢1%, F: 43¢9%

F: 18¢1%

Smoking more: 18¢9% (unclear if

(2019)

includes initiation)

Smokers

Smoking less: 14¢1% (reduced only −
no quitting)
Increased motivation/desire to quit:
16¢1%
Decreased motivation/desire to quit:
12¢1%

Poland
Chodkiewicz33

Social media

Convenience;

Online

10−29 April

S + NS

443,

snowballing

Mean: 31¢9 (SD:

25¢5%
(113/443)

22¢4%

Smoking changes

M: 25¢8%

All participants

11¢3),

F: 19¢2%

Smoking less: 5¢0% (22/443)

M: 21¢4%, F:

(2019)

78¢6%

(unclear if includes quitting)
Smokers
Smoking more: 23¢0% (26/113)
(unclear if includes initiation)
Smoking less: 19¢5% (22/113)
(unclear if includes quitting)

Sidor50

Social media

Convenience

Online

17 Apr - 1 May

S + NS

1097,
18−25: 53¢6%,

14¢1%

Smoking changes

(155/1097)x

Smokersx

26−45: 41¢4%,

Smoking more: 45¢2% (70/155)

46+: 4¢9%,

(unclear if includes initiating)

M: 4¢9%, F:
95¢1%

Spain
Lopez-Bueno41

Social media

Convenience

Online

22 Mar - 5 Apr

S + NS

2741,
Mean: 34¢2 (SD: 13¢0),
M: 48¢2%, F: 52¢8%

13¢9%
(382/2741)

24¢4%

Smoking prevalence

M: 28¢2%

Before pandemic: 13¢9% (382/2741)

F: 20¢8%

During pandemic: 8¢8% (241/2741)

(2016−2017)4

Articles
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United Kingdom
Jacksona39

Media consumers,

Convenience

NR

21 Mar - 20 Apr

S + NS

53,221 (unweighted)

14¢1%

15¢2%

Smoking changes

digital users, and

18−29: 10¢4%, 30−49:

(8057/53,002;

M: 15¢9%

All participants

vulnerable

40¢8%, 50+: 48¢8%

weighted

F: 12¢5%

Smoking less: 2¢0% (weighted per-

groups

(unweighted percen-

percentage)

(2019)

centage) (reduced only − no quit-

tages),

ting)

M: 26¢4%, F: 73¢6%

Smokers

(unweighted

Smoking more: 42¢2% (weighted per-

percentages)

centage) (unclear if includes initiation)
Smoking less: 13¢4% (weighted percentage) (reduced only − no
quitting)

Taylorz,52

Ongoing study

Unclear

Online

27 May - 8 Jun

S + NS

1¢1%

190,

(Lothian Birth

Mean: 84 (SD: 0¢3),

Cohort 1936)

M: 52¢7%, F: 47¢3%

Smoking prevalence

(2/189)

Before pandemic: 1¢1% (2/189)
During pandemic: 1¢1% (2/189)
Smoking changes
All participants
Smoking less: 0¢0% (0/189) (reduced
only − no quitting)
Smokers
Smoking more: 50¢0% (1/2) (unclear
if includes initiation)
Smoking less: 0¢0% (0/2) (reduced
only − no quitting)
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Stopped smoking: 0¢0% (0/2)

United States
Chertok32

Social media; email

Convenience

Online

7−20 Apr
(exact end date unclear)

S + NS

810,
Mean: 33¢5 (SD:

22¢1%

20¢8%

Smoking changes

M: 24¢9%

All participants

14¢6),

F: 17¢1%

Smoking less: 8¢5% (69/810)

M: 27¢5%, F:

(2019)

(reduced or quit)

72¢5%

(179/810)

Smokers
Smoking more: 18¢3% (33/180)
(unclear if includes initiation)

Table 1a (Continued)
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United States
Smoking less: 38¢3% (69/180)
(reduced or quit)
Increased motivation/desire to quit:
51¢7% (93/180)
Decreased motivation/desire to quit:
12¢2% (22/180)
Attempted to quit: 36¢7% (66/180)
Emerson37

Social media, email

Convenience;

Online

30 Mar - 12 Apr

S + NS

snowballing

833,

NR

Smoking changes

60−70: 62¢8%,

All participants

71+: 37¢2%,

Smoking more: 1¢3% (unclear if

M: 19¢5%, F:

includes initiation)

80¢5%

Smoking less: 1¢1% (unclear if
includes quitting)

Knell40

Social media

Convenience

Online

15 Apr - 5 May

S + NS

1809,
18−34: 31¢5%,

9¢8%

Smoking changes

(177/1809)

All participants

35−49: 39¢8%,

Smoking less: 1¢9% (34/1809)

50+: 28¢7%,

(unclear if includes quitting)

M: 32¢6, F: 67¢4%

Smokers
Smoking more: 30¢5% (54/177)
(unclear if includes initiation)
Smoking less: 19¢2% (34/177)
(unclear if includes quitting)

Rogers48

Crowdsourcing website

Convenience

Online

Apr - May

S + NS

160,
Mean: 37¢9 (SD:

21¢9%

Smoking changes
Non-smokers

(35/160)

11¢2),

Started smoking: 8¢8% (11/125)

M: 56¢5%, F:
43¢5%

Zimbabwe
Matsungo44

Social media, email

Convenience

Online

11−25 May

S + NS

507,

14¢4%

NR

Smoking changes

18−30: 26¢0%, 31−40: 48¢1%, 50+: 10¢5%,

(Percentage esti-

M: 17¢7%

M: 37¢0%, F: 63¢0%

mated by review

F: 0¢5%

Smoking less: 4¢9% (percentage esti-

team from Fig. 3;

(2015)

mated by review team from Fig. 3)

All participants

n participants in

(unclear if includes quitting)

Fig. 3= 421)

Smokers

Table 1a (Continued)
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Zimbabwe
Smoking more: 45¢9% (unclear if
includes initiation)
Smoking less: 30¢6% (percentage
estimated by review team from
Fig. 3) (unclear if includes quitting)

9 European countries: Bosnia and Herzegovina, Croatia, Greece, Italy, Kosovo, Serbia, Slovakia, Slovenia, Spain
Pisot46

Website; email

Convenience;
snowballing

Online

Bosnia and Herze-

S + NS

4108,

govina, Croatia,

Mean: 32¢0 (SD: 13¢2),

Serbia, Slova-

M: 37¢2%, F: 62¢8%

35¢9%
(1476/4108)

Bosnia and Herzegovina: NR
Croatia: 35¢0%

Smoking changes
All participants

(M: 40¢0%; F: 31¢0%) (2017)

Smoking less: 14¢1% (579/4108)

Greece: 27¢1%

(unclear if includes quitting)

Italy & Spain: 15

(M: 24¢6%; F: 29¢6%) (2017)

Smokers

Apr - 28 May

Italy: NA

Smoking more: 22¢2% (328/1476)

Kosovo: 24 Apr -

Kosovo: NR

(unclear if includes initiation)

3 May

Serbia: NR

Smoking less: 39¢2% (579/1476)

Greece: 28 Apr -

Slovakia: 26¢0%

(unclear if includes quitting)

kia, Slovenia,

3 May

(M: 34¢0%; F: 19¢0%) (2017)
Slovenia: 24¢3%
(M: 27¢5%; F: 21¢2%) (2014)4
Spain: 24¢4% (M: 28¢2%;
F: 20¢8%) (2016−2017)4

Table 1a: Description of studies included in the meta-analyses.
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* Social media includes websites and digital applications used for social networking, such as Facebook, WhatsApp and Twitter.
y
If only percentage shown, exact numbers NR by study.
z
Pre-print.
x
Addicted to smoking, so unclear if 155 is the total number of smokers or if there are more (e.g., occasional smokers).S: Smokers, NS: Non-smokers; M: Male, F: Female; SD: Standard deviation; Q1-Q3: Quartile 1 to quartile 3;
NR: Not reported, NA: Not applicable.

Sampling

method

Population

source

Participants
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NR

Mean: 543 (SD:
130),

cohort)

demic:

NEXT birth
cohort: NR

159,
Mean: 330 (SD:

2062,

interviews

15−30: 201%,

no initiation)
Smoking less:

15%

(reduced only − no

683% (1210/1772)

(increased only −

182% (323/1772)

Smoking more:

Smokers

Smoking changes

M: 985%, F:

(2017−2018)

F: 47%

M: 226%

7 days?“)z

the last

51+: 324%,

NR

Mean: 450 (SD: 145)

Wave 2:

tablet assisted

5 May - 4 Jun

78% (“Have

635%

Sep 2019 - Feb 2020

combined:

M: 365%, F:

you smoked in

both cohorts

43),

Face-to-face and

31−50: 475%,

137%

During pan-

Lifelines

birth cohort

NA

birth cohort: NR

140%

Presumably,

Lifelines NEXT

last visit”:

Lifelines NEXT

smoker “at last

140% (current

tion cohort:

608%

Telephone

Lifelines pro-

visit”)z

Wave 2

demic:

(2019)

spective popula-

Before pan-

F: 181%

Smoking prevalence

reported*

Outcomes

M: 254%

217%

WHO estimate

68

smoker “at

Current

cohort:

lation

tive popu-

prospec-

Lifelines

Before pan-

NR

Online

study

Reported by

demic:

18 Mayy

Surveymode

NR

38,086y

(2020)

period

Survey

Tobacco smoking prevalence

M: 392%, F:

Lifelines NEXT

2006-last visit

tion cohort

NR

6014,

Wave 1

68,501,

NEXT birth

S

2016-last visit

tion cohort

the Lifelines

Random sample

birth cohort

spective popula-

tion cohort and

spective popula-

Lifelines pro-

Lifelines pro-

68,660, comprising

spective popula-

S + NS
two cohorts:

Unclear

(Lifelines pro-

Ongoing study

Table 1b (Continued)

Siddiqi58

Pakistan

McIntyre56

Netherlands
2006-last visit

N, age, sex

Sample
characteristics:

Surveymode

N, age, sex

Survey period

During COVID-19 pandemic

characteristics:

Sample

Before COVID-19 pandemic

Single cohort with longitudinal follow-up (same participants sampled before and during COVID-19 pandemic)

Country / Authors

Articles

13

14

Articles

Pakistan
quitting)
Stopped smoking:
141% (290/2062)

United Kingdom
Niedzwiedz57

Ongoing study

Mixed mode (face-

Same as before

(UK Household

Representative

S + NS

9748 ,
18−24: 64%,

2017−2019

to-face, tele-

pandemic

Longitudinal

25−44: 291%,

Study)

45+: 644%

24−30 Apr

Online

Before pandemic:

141%

Smoking prevalence

151%

M: 159%

Before pandemic:

phone or online

(weighted per-

F: 125%

151% (weighted

survey)

centage)

(2019)

percentage)

(weighted per-

During pandemic:

centages),

121% (weighted

M: 443%, F:

percentage)

557%
(weighted
percentages)

Multiple cross-sectional cohorts (different participants sampled before and during COVID-19 pandemic)
United Kingdom
Jacksonb55

Ongoing study

Representative

S + NS

Monthly,

18,884,

Face to face and

1674,

Apr

Telephone

Before pandemic:

141%

Smoking prevalence

computer-

16−24: 109%,

159%

M: 159%

Before pandemic:

25−44: 326%,

assisted

25−44: 332%,

(weighted

F: 125%

159% (weighted

45+: 540%

interviews

45+: 555%

percentage)

(2019)

percentage)x

(Smoking and

16−24: 134%,

Alcohol Toolkit
Studies)

Apr 2019 - Feb 2020

www.thelancet.com Vol 47 Month May, 2022

(weighted per-

(weighted per-

During pandemic:

centages),

centages),

170% (weighted

M: 491%, F:

M: 491%, F:

percentage)x

509%

509%

(weighted

(weighted

percentages)

percentages)

Table 1b: Description of studies included in the meta-analyses.
pandemic).

B. Before-and-during studies 104,980 participants in 4 studies (103,306 participants before pandemic and 51,552 participants during

* If only percentage shown, exact numbers NR by study.
y
Personal communication with study authors.
z
Estimates effectively unadjusted for potential confounding factors, as study had same participants before and during the pandemic, but with substantial loss to follow-up.
x
Estimates effectively unadjusted for potential confounding factors, as study had different participants before and during the pandemic.S: Smokers, NS: Non-smokers; M: Male, F: Female; SD: Standard deviation; NR: Not
reported, NA: Not applicable.
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We carried out separate quantitative syntheses for populations unselected for smoking status and for populations restricted to smokers or non-smokers for each
outcome (smoking prevalence, smoking initiation,
smoking cessation, smoking increase, smoking
decrease, intention to quit and attempts to quit). We
used the random-effects method to pool data. Heterogeneity among included studies was assessed visually and
statistically, using the I-squared statistic (I2) and Chisquared test. For the meta-analyses of smoking increase
and decrease, we performed a sensitivity analysis
including only studies that reported both of these outcomes. We intended to perform subgroup meta-analyses to examine heterogeneity in effect estimates based
on: age, sex, country, change in socio-economic circumstances (e.g., employment status), psychological and
mental health factors (e.g., anxiety), and peer-review status. We could not conduct these subgroup analyses as
there were no more than two studies reporting data on
an outcome for the subgroups of interest. Meta-regression was used to assess the relationships between the
included outcomes and (1) the severity of COVID-19
outbreaks in the study population and period (number
of COVID-19 cases or deaths per capita between the
start and end dates of the survey and also from the start
date of the pandemic to the end date of the survey),13 (2)
the mean daily stringency index of the national
response to the COVID-19 pandemic during the survey
period,13 and (3) the proportion of survey participants
who were male, if reported for the study. Meta-regression was used when there were at least 10 studies for
the outcome-predictor combination.

excluded publication type or study design (Supplementary Table 2). 44 studies met the inclusion criteria of
which 13 were excluded from the meta-analyses due to
insufficient or inconsistent data (described in Supplementary Table 5),16−28 with 31 studies remaining (27
cross-sectional7,29−54 and 4 before-and-during,55−58
described in Tables 1a and 1b, respectively).
Smoking data were collected from a total of 269,164
participants across 24 countries (including one study
conducted across nine European countries). In most
studies, the majority of participants were female (23/30
studies, where reported). The 27 cross-sectional studies
included 164,184 participants surveyed between 14 February and 30 August 2020 (predominantly in AprilMay). Recruitment was via social media for over half of
the studies. 25 of the studies that included both smokers
and non-smokers reported smoking prevalence data. 17
studies reported outcomes for a subgroup of smokers,
and eight studies reported outcomes for smokers only.
The four before-and-during studies included 104,980
participants. Surveys for these studies were conducted
from 2006 up to February 2020 before the pandemic,
and from April to 4 June 2020 during the pandemic,
with a minimum of two months to a maximum of
14 years between surveys. Three studies sampled participants from ongoing cohort studies and reported smoking prevalence: two studies re-surveyed the same
participants, while the other study surveyed a different
group at each time point. The fourth study assessed
changes in smoking prevalence and behaviours
amongst smokers across multiple waves during the
COVID-19 pandemic, with follow-up of some participants previously surveyed.

PROSPERO registration
The PROSPERO registration number for this systematic review was CRD42020206383 (https://www.crd.
york.ac.uk/prospero/display_record.php?
ID=CRD42020206383).

Role of the funding source
No specific funding was received for this study. Funding
sources had no role in study design, data collection, data
analysis, data interpretation, writing of the report, or in
the decision to submit the paper for publication. All
authors had access to the data in this study and agreed
to submit the article for publication.

Results
Summary of the studies included
Searches of published and pre-print literature identified
17,359 unique records, with an additional 158 records
identified from citations (Figure 1). 213 articles that
underwent full text screening were ineligible; most as
they did not report an outcome of interest or were an

www.thelancet.com Vol 47 Month May, 2022

Prevalence of smoking during compared to before the
pandemic
12 studies (9 cross-sectional, 3 before-and-during) were
included in the meta-analysis for changes in smoking
prevalence during versus before the pandemic
(Tables 1a, 1b and 2), the combined prevalence ratio
being 0¢87 (95%CI:0¢79−0¢97), indicating a relative
reduction in the prevalence of smoking during the pandemic (Figure 2a) although the pooled estimate should
be interpreted with caution due to the very high heterogeneity (I2 = 99¢3%, p < 0¢001; see Discussion below).
Meta-regression analyses showed no significant relationship between prevalence ratios and COVID-19 cases
per capita, COVID-19 deaths per capita, mean daily
stringency indexes or the proportions of survey participants who were male (p-values ranged from 0¢215 to
0¢766; Figure 2b shows meta-regression for stringency
indexes).

Smoking more, less or unchanged among smokers during the pandemic. Twenty-two cross-sectional studies

15
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Figure 1. Flow diagram based on the PRISMA 2020 ﬂow chart summarising the article screening process.
The characteristics and outcomes of all 44 included studies are described qualitatively. Studies included in the quantitative synthesis had sufﬁcient data for pooling in a meta-analysis and are described in Tables 1a, 1b. Studies with insufﬁcient or inconsistent
data excluded from the quantitative synthesis are described in Supplementary Tables 5a and b. *Excluded publication type or study
design, or letter or comment without relevant primary data. ^The full text of one study was unable to be retrieved for eligibility
assessment (French, M., et al., 2020. PMID: 32853158).

were included in meta-analyses of smoking less (n = 17),
smoking more (n = 22), or unchanged smoking (n = 17)
among smokers (Tables 1a, 1b and 2). The pooled proportions were: 21% (95%CI:14−30%) for smoking less,
27% (95%CI:22−32%) for smoking more, and 50%
(95%CI:41−58%) calculated to have unchanged smoking intensity during the COVID-19 pandemic. Heterogeneity was high in the three meta-analyses: all
I2 > 98%, p < 0¢001 (Table 2 and Figure 3). The results
for smoking more and smoking less among all survey
respondents are described in the Additional Results
(Supplementary material p.3) and shown in Table 2 and
Supplementary Fig. 1. A sensitivity analysis including
only studies that reported both smoking more and
smoking less is shown in Supplementary Fig. 2.

Started smoking or quit smoking (including motivation and attempts to quit) during the pandemic. Six
studies provided usable data on the proportion of smokers who quit during the COVID-19 pandemic
(Tables 1a, 1b and 2): the pooled proportion was 4%
(95%CI:1−9%) with high heterogeneity (I2 = 94¢8%,
p < 0¢001) (Figure 4a). Additionally, four studies provided data on starting or restarting smoking during the
pandemic among non-smokers, the pooled proportion
being 2% (95%CI:1−3%) with high heterogeneity

16

(I2 = 91¢7%, p < 0¢001) (Figure 4b). For smokers, two
studies reported increased motivation or desire to quit
smoking (pooled proportion 21%, 95%CI:18−23%,
Figure 4c), two studies reported decreased motivation or
desire to quit smoking (pooled proportion 12%,
95%CI:10−14%, Figure 4d), and only one study reported
attempts to quit smoking (proportion 37%, 95%CI:33
−40%, Table 2). Heterogeneity was not calculated for
these estimates due to a small number of studies.

Risk of bias
All 27 cross-sectional studies included in meta-analyses
had high risk of bias (Table 3a) with the major source of
bias being that study populations were not representative of the target population, as 23 studies used convenience samples with online questionnaires distributed
via social media, websites, and/or mailing lists, and
four studies contacted online or mobile phone panels.
Of the four before-and-during studies, one had overall
moderate risk of bias, two had serious risk of bias, and
one had critical risk of bias (Table 3b). The two major
sources of bias were selection of participants into the
study, mainly due to non-representative participants or
low response rates, and in the measurement of the outcome with different methods and/or tools/questions
used before and during the pandemic.
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Figure #

Outcome

Participants

Number of
participants

Number of
studies

Pooled effect
estimate (95%CI)

I2 (p-heterogeneity)

2.a.

Smoking prevalence

S + NS

125,246

12

0¢87 (0¢79−0¢97)

99¢3% (<0¢001)

ratio (during vs
before)
3

Prevalence among

3.a.

Smoking less

S

22,335

17

21% (14−30%)

99¢4% (<0¢001)

3.b.

Smoking more

S

23,805

22

27% (22−32%)

98¢5% (<0¢001)

3.c.

Smoking unchanged

S

22,690

17*

50% (41−58%)

99¢2% (<0¢001)

4

Prevalence among non-

smokers (%)

smokers or smokers
(%)
4.a.

Stopped smoking

S

4184

6

4% (1−9%)

94¢8% (<0¢001)

4.b.

Started smoking

NS

10,341

4

2% (1−3%)

91¢7% (<0¢001)

4.c.

Increased motivation or

S

1137

2

21% (18−23%)

Not calculable

S

1137

2

12% (10−14%)

Not calculable

S

180

1

37% (33−40%)

Not calculable

desire to quit
4.d.

Decreased motivation
or desire to quit

−

Attempted to quit

Suppl. 1

Prevalence among all
survey respondents
(%)

Suppl. 1.a.

Smoking less

S + NS

140,287

17

3% (2−5%)

99¢1% (<0¢001)

Suppl. 1.b.

Smoking more

S + NS

14,218

5

4% (1−8%)

99¢0% (<0¢001)

Table 2: Summary estimates of smoking prevalence and smoking behaviour changes, among 269,164 participants in 31 studies.
* Only studies that reported the outcomes of both smoking more and smoking less. S: Smokers, NS: Non-smokers.

Discussion
This is the first systematic review and meta-analyses of
changes in smoking behaviours during the early phases
of the COVID-19 pandemic. The prevalence of smoking
during the COVID-19 pandemic was observed to be
lower than pre-pandemic in most of the included studies, with the pooled prevalence ratio suggesting a 13%
(95%CI:3−21%) relative decline in smoking prevalence
(high heterogeneity: I2 = 99¢3%, p < 0¢001). Among
people who smoke, changes in amount smoked during
the pandemic varied between studies, with 21%
(95%CI:14−30%) of people who smoke reporting smoking less, 27% (95%CI:22−32%) smoking more, and
50% (95%CI:41%58%) with unchanged smoking
(high heterogeneity: all I2 > 98%, p < 0¢001). Further,
4% (95%CI:1−9%) of people who smoke reported quitting smoking, while 2% (95%CI:1−3%) of people who
did not smoke started (high heterogeneity: both
I2 > 91%, p < 0¢001). We note that the pooled estimate
of 4% of smokers who reported quitting is based on different studies compared to the pooled estimate of an
overall 13% relative decline in smoking prevalence, and
are thus not directly comparable. Given the rapid
response of these studies to the onset of the pandemic,
most were cross-sectional with convenience samples
recruited via social media and other online platforms
and almost all were at high risk of bias. However,
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they offer an informative and indicative first look at
the impact of the pandemic on consumption of the
world’s most lethal legal consumer product. Importantly, the included studies represent many different
populations, offering an international snapshot of
this issue.
The reduction in the proportion of participants who
reported smoking during the pandemic is an encouraging result. Although all but two included studies were
not representative, such observed decreases in smoking
prevalence could be leveraged to inform tobacco control
policies within individual settings to support continued
decreases over time. Some public health measures
implemented during the pandemic to control COVID19 outbreaks also represent an opportunity to study
interventions that may reduce exposure to non-communicable disease risk factors, including smoking. For
example, during lockdown in South Africa the sale of all
tobacco products was banned, and in one South African
study 9% of people who smoked quit during the pandemic.59 It is important to note that smoking prevalence
in many of the countries in Europe and North America
represented here had already been declining prior to the
pandemic, albeit at different rates.60 As nationally representative tobacco surveillance reports become available, the picture will become clearer for individual
countries.
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Figure 2. a. Meta-analysis of prevalence ratios for smoking prevalence during early COVID-19 pandemic (2020) compared to smoking prevalence before COVID-19 pandemic.
*Prevalence ratios less/more than one indicate a reduction/increase in smoking prevalence during the COVID-19 pandemic,
respectively. Surveys are cross-sectional (n = 9) that asked participants about their smoking behaviour before (retrospectively) and
during the pandemic, or longitudinal (n = 3, Jacksonb, McIntyre and Niedzwiedz) that asked participants about their smoking behaviour contemporaneously before and during the pandemic. CI: Conﬁdence interval. Fig. 2b. Meta-regression of smoking prevalence
ratios for smoking prevalence during COVID-19 pandemic compared to smoking prevalence before COVID-19 pandemic by mean
daily stringency index during the study survey period.
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The results with respect to changes in smoking
intensity were diverse with similar proportions of people who smoke increasing their intake or reducing their
intake, and approximately a half retaining previous levels of smoking intensity. Understanding the causes of
smoking behaviour changes is important, as it assists in
quantifying potential long-term impacts and identifying
best intervention measures to support recovery and
future prevention. The mixed response we report in this
systematic review likely reflects a complex interplay
between individual, societal, and systemic factors.7−9
Individual factors include: (a) perceived risks of exposure to severe illness or death from COVID-19; (b) feelings of uncertainty, for example regarding one’s own
health, the health of loved ones, and economic insecurity; and (c) the psychological stress response to these
factors, experienced in the context of one’s physical and
mental health, economic situation, and related vulnerabilities. Factors that influence COVID-19 risk such as
health and public health systems, government
responses to the pandemic (i.e. degree of strictness and
of enforcement) and pre-existing health disparities and
social inequities, as well as factors such as tobacco control policies before and during the pandemic, can all
influence individuals’ tobacco use behaviours. Tobacco
product scarcity in certain countries at the start of the
pandemic may also have influenced smoking behaviours, potentially positively due to reduced supply of
tobacco or negatively due to increased smoking of
tobacco after ‘stocking up’.61 Overall, the evidence
for changes in tobacco smoking in response to the
COVID-19 pandemic highlights the importance of
public health campaigns for tobacco cessation and
for enhancing resources for, and access to, tobacco
cessation services.7
It is yet to be determined whether short-term
changes in smoking patterns reported here translate
into long-term, sustained changes. There is evidence
that some lifestyle behaviours persist for some time
after a pandemic. For example, individuals in China
who were quarantined or worked in high-risk locations
during the 2003 SARS epidemic were more likely to
use alcohol as a coping mechanism, and this was significantly associated with increased alcohol abuse/dependence symptoms three years after the outbreak.62 It is
also possible that changes in smoking during the early
phase of the pandemic may not be sustained or indicative of changes that occur in later phases as living with
COVID-19 becomes a norm.63 Further, the adverse

impact of the COVID-19 pandemic on smoking is
expected to be most pronounced for already disadvantaged groups, potentially leading to exacerbated health
disparities. This potentially includes population subgroups with disproportionately higher rates of smoking
including those with pre-existing medical, psychiatric,
or substance use problems, or those with low socio-economic status, or who are marginalised for other reasons
(e.g.64−67). There is also a need for studies focussed on
youth, as any impact on them is likely to have the largest
impact on long-term smoking rates. Given potential differences in COVID-19 outcomes by sex,68 it may be
important to consider smoking changes disaggregated
by sex as well. These subgroups should be highlighted
for future research.
Our review should be a driver for researchers to
develop tools to support high quality harmonized data
collection, including validated questions measuring
changes in tobacco smoking during and after the pandemic, and for standardised platforms to collect these
data. The reported results are also valuable for informing realistic ranges of values that can be used for modelling. Modelling studies can be a valuable tool enabling
the prediction of the disease burden, outcomes, and
resource utilisation for the whole population as well as
for specific subgroups by sex, age, or socio-economic
status, especially if the pandemic had a differential
impact on population subgroups. Such evaluations are
planned by the COVID-19 and Cancer Global Modelling
Consortium (CCGMC; https://ccgmc.org/) which has a
working group dedicated to assessing the impact of the
pandemic on cancer risk. An important goal of the
CCGMC is to inform best practices in cancer prevention
in order to mitigate the long-term impact on future cancer burden. One important aspect of the CCGMC
endeavours will be to assess the overall direct and indirect effects of the pandemic on cancer outcomes, considering changing exposure to risk factors (as here),
pauses or reduced participation in cancer screening programmes, delays to detection of symptomatic cancer,
the direct impact of COVID-19 infection on mortality in
cancer patients, and the indirect effects of delays and
disruptions to cancer treatment. These complex effects
will play out in different timescales and to different
degrees in different settings, and policy-makers will
require clear information on best-practice response and
prioritisation strategies. The CCGMC will continue to
monitor changes in smoking and other risk factors in
response to the COVID-19 pandemic.

Prevalence ratios less/more than one indicate a reduction/increase in smoking prevalence during COVID-19 pandemic, respectively. Surveys are cross-sectional (n = 9) that asked participants about their smoking behaviour before (retrospectively) and during
lockdown, or longitudinal (n = 3, Jacksonb, McIntyre and Niedzwiedz) that asked participants about their smoking behaviour contemporaneously before and during lockdown.
Repeated countries are due to different studies being conducted in the same countries.
The OxCGRT Stringency Index is a measure of variation in governments’ responses to COVID-19 and is an additive score of nine
indicators (such as school closures, travel bans, etc.) rescaled to vary from 0 to 100.10
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Figure 3. Meta-analysis of proportion (effect estimates, ES) of smokers who reported: (a) smoking less, (b) smoking more and (c)
smoking unchanged during the COVID-19 pandemic.
*A sensitivity analysis including only studies that reported both smoking more and smoking less is presented in Supplementary
Fig. 2. yProportions for unchanged smoking were calculated only for those studies that reported both more and less smoking as 1ES(more)-ES(less). CI: Conﬁdence interval.

The included studies in this review have limitations.
The majority were carried out using convenience samples, and 20 of 31 studies used surveys distributed via
social media. The reported estimates are therefore
unlikely to be representative, and overall smoking

20

prevalence estimates from different surveys in the same
country varied considerably. Almost all studies had a
high risk of bias, often due to the use of unvalidated survey questions that place limitations on the interpretability and comparability of the resulting estimates. Many
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Figure 4. Meta-analysis of smoking behaviour changes for (a) proportion (effect estimates, ES) of smokers who stopped smoking, (b)
proportion of non-smokers who started smoking, (c) proportion of smokers who had an increased motivation or desire to quit, (d)
proportion of smokers who had a decreased motivation or desire to quit during the COVID-19 pandemic.
For plot (a) surveys are cross-sectional (n = 4) that asked participants about their smoking behaviour before (retrospectively) and
during COVID-19 pandemic, or longitudinal (n = 2, Jackson and Siddiqi) that asked participants about their smoking behaviour contemporaneously before and during COVID-19 pandemic. For plot (b) surveys are cross-sectional that asked participants about their
smoking behaviour before (retrospectively) and during lockdown. *For plots (c) and (d) heterogeneity estimates were not calculable
as there were only 2 studies. CI: Conﬁdence interval.
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1. Was the study
population a close
representation of
the target
population in
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relevant
variables, e.g.
age, sex?

2. Was the
sampling frame a
true or close
representation of
the target
population?

3. Was some
form of
random
selection
used to select
the sample,
OR, was a
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undertaken?

4. Was the
likelihood of
non-response
bias minimal?

5. Were data
collected
directly from
the subjects
(as opposed
to a proxy)?

6. Was an
acceptable
deﬁnition of
change in
smoking
behaviour
used in the
study?*

7. Were the
survey
questions
that
measured the
parameter of
interest (e.g.
prevalence of
smoking
behaviour
changes)
shown to
have
reliability and
validity?*

8. Was the
same mode of
data
collection
used for all
subjects?

9. Were the
numerator(s)
and
denominator
(s) for the
parameter of
interest
appropriate?*

Overall
risk of bias

Ahmed29
Asiamah30
Bommele7
Cancello31
Chertok32
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Chopra34
Constant35
Di Renzo36
Emerson37
Georgiadou38
Jacksona39
Knell40
Lopez-Bueno41
Luk42
Malta43
Matsungo44
Odone45
Pisot46
Ren47
Rogers48
Rolland49
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Sun51
Taylor52
Vanderbruggen53
Yan54
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High
High
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High
High
High
High
High
High
High
High
High
High
High
High

High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High

High
High
High
High
High
High
High
Low
High
High
High
High
High
High
Low
High
High
High
High
High
High
High
High
High
High
High
High

High
High
High
High
High
High
High
Low
High
High
High
High
High
Low
High
High
High
High
High
High
High
High
High
High
Low
High
High

Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
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Low
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Moderate
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Low
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High
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High
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Low
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Low
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Low
High
Mixed*
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High
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High
High
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High
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High
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High
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High
High
High
High
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Table 3a: Risk of bias for cross-sectional studies included in quantitative analyses.

* Risk of bias assessed separately for each included study outcome.yLow risk of bias for some outcomes (smoking prevalence, quit smoking) and Moderate risk of bias for others (initiate smoking, relapse, increase smoking,
change from occasional to regular smoking).
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1. Selection of
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2. Measurement
of outcome

3. Confounding

4. Missing
data

5. Selection of
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Jackson55

Moderate

Moderate

Low

Low

Low

Moderate

McIntyre56

Critical

Critical

Serious

Serious

Low

Critical

Niedzwiedz57

Moderate

Serious

Low

Low

Low

Serious

Siddiqi58

Serious

Serious

Low

Low

Low

Serious

Table 3b: Risk of bias for before-and-during studies included in quantitative analyses.

studies also reported estimates that either combined
several qualitatively different groups (e.g., those who
never smoked and those who reduced smoking), did not
report results for all outcomes available, did not report
standard errors, or did not use appropriate denominators or numerators. Further, the question wording used
in each survey was highly variable from study to study,
and interpretation was made difficult by the fact that
many studies did not provide detail about the specific
questions asked, nor adequate information describing
how responses were analysed. We have used the definitions of each smoking behaviour change as reported in
the included studies, where these were reported. Two
studies provided estimates that were effectively unadjusted for potential confounding factors, with one study
involving different participants before and during the
pandemic,55 and one study involving the same participants before and during the pandemic but with substantial loss to follow-up.56 Finally, given the limited data on
the differences in the timing and extent of COVID-19
outbreaks and measures taken to control the pandemic
between countries and contexts, and on pre-pandemic
trends in smoking prevalence, we also cannot infer any
causal relationships between the pandemic and specific
aspects of smoking behaviour changes. Some studies
specifically asked whether a participant’s smoking
behaviour changed due to the pandemic or lockdown,
however these studies were still considered at high risk
of bias for the aforementioned reasons.
We note that caution must be taken in the interpretation of the meta-analyses due to the high statistical heterogeneity for each of the outcomes examined (I2>91%,
p<0¢001), reflecting the differences in methods and
high risk of bias for the included studies and the differences in the impact of the pandemic in different populations and around the world. Nonetheless, we believe
that the meta-analyses presented here provide useful
information consolidating evidence on the range of
changes to date, and that the assessment of heterogeneity from the meta-analyses is in itself informative for
the appraisal of the evidence base on this topic. Moreover, a recent study69 systematically sampled 134 published meta-analyses of prevalence and found that the
median I2 was 96¢9% (IQR: 90¢5% to 98¢7%), concluding that “. . .in meta-analyses of prevalence, I2 statistics
may not be discriminative and should be interpreted with
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caution, avoiding arbitrary thresholds”. This supports the
reporting of meta-analyses to estimate the pooled prevalence even when heterogeneity is high, with the appropriate caveats regarding interpretation as highlighted
above.
The approach and methods used for our review have
notable strengths, including a rigorous risk of bias
assessment using tools customised for this review. The
full-text screening, data extraction, and risk of bias
assessments were all carried out in duplicate. Moreover,
we used representative estimates of smoking prevalence
from the WHO to help contextualise and interpret estimates from the included studies.70 The limitations of
our review include that titles and abstracts were only
screened by one reviewer; however, we checked the
references of articles included in full-text screening to
identify any additional relevant studies. Also we did not
contact authors of the original studies for clarification.
The pooled estimates derived from meta-analyses are
prone to the biases found in the original studies, including differences in the definitions of smoking behaviours
between studies. Our review did not include grey literature such as national and jurisdictional surveys carried
out by governments and other organisations, which
may provide more representative data; a dedicated
search of such surveys is planned by the CCGMC.
To conclude, there was considerable variation in
smoking behaviour changes during the early pre-vaccination phases of the COVID-19 pandemic in 2020. Our
meta-analyses indicate a relative reduction in overall
smoking prevalence during the pandemic, while similar
proportions of people who smoke smoked more or
smoked less, although statistical heterogeneity was
high and the pooled estimates should be interpreted
with caution. The implementation of tobacco control
measures and the delivery of tobacco cessation services, by adhering to policies and procedures such as
those set out by the Framework Convention on
Tobacco Control,71 have an important role in ensuring that the COVID-19 pandemic does not exacerbate
the smoking pandemic and its associated adverse
health outcomes.
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